Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 102, Issue 4, Pages 869-877Publisher
WILEY
DOI: 10.1002/jcb.21519
Keywords
cyclins; proteolysis; ubiquitin; proteasome; ISG15-UBE1L; cancer therapy; cancer chemoprevention
Categories
Funding
- NCI NIH HHS [R03 CA130102, R01 CA111422, R01 CA087546, R01 CA062275, T32 CA009658] Funding Source: Medline
Ask authors/readers for more resources
Cancer is characterized by uncontrolled cell division resulting from multiple mutagenic events. Cancer chemoprevention strategiesaim to inhibitor reverse these events using natural or synthetic pharmacologic agents. Ideally, this restores normal growth control mechanisms. Diverse classes of compounds have been identified with chemopreventive activity. What unites many of them is an ability to inhibit the cell cycle by specifically modulating key components. This delays division long enough for cells to respond to mutagenic damage. In some cases, damage is repaired and in others cellular damage is sufficient to trigger apoptosis. It is now known that pathways responsible for targeting G1 cyclins for proteasomal degradation can be engaged pharmacologically. Emergence of induced cyclin degradation as a target for cancer therapy and chemoprevention in pre-clinical models is discussed in this article. Evidence for cyclin D1 as a molecular pharmacologic target and biological marker for clinical response is based on experience of proof of principle trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available